

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
5	BRS	L7	0	6 same 2	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 17:58			0
6	BRS	L8	32	4 near (human or murine or rabbit or rat)	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 17:58			0
7	BRS	L9	0	8 same 2	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 17:58			0
8	BRS	L11	36	(limulus adj anti-LPS adj factor) or LALF	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 18:00			0
9	BRS	L14	0	12 same 2	USPAT	2001/06/04 18:02			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
10	BRS	L15	78	4 same (treating or treatment)	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 18:04			0
11	BRS	L16	1069	(bactericidal adj permeability adj increasing adj protein) or BPI	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 18:06			0
12	BRS	L17	99	(16 or 11) same 4	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 18:38			0
13	BRS	L18	11	17 same (hybrid adj protein)	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 18:40			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
14	BRS	L19	26	17 same (fusion adj protein)	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 18:45			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L2	1492	septicemia	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 17:54			0
2	BRS	L4	1957	lbp or (liposaccharide adj binding adj protein)	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 18:03			0
3	BRS	L5	0	2 same 4	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 17:55			0
4	BRS	L6	71	4 same (variant or mutant or hybrid)	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 17:57			0

from *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Serratia marcescens*; a (2) bactericidal activity against these same four gram-negative bacteria in vitro. RESULTS. Synthetic peptides BG38 (BPI-derived), BG42 (\*\*\*LALF\*\*\* -derived), and BG43 (\*\*\*LBP\*\*\* -derived) but not control peptide significantly inhibited LPS-induced tumor necrosis factor- $\alpha$  secretion by macrophages and mediated the lysis of gram-negative bacteria in vitro. In addition, preincubation of LPS with peptide BG38 mediated complete protection subsequent to lethal endotoxin challenge. CONCLUSIONS. These data demonstrate that small peptides derived from BPI, \*\*\*LALF\*\*\*, and \*\*\*LBP\*\*\* retained significant endotoxin-neutralizing and bactericidal activity against many different gram-negative bacteria in vitro. Identification of this conserved LPS-binding region within each protein may aid in the development of new immunomodulatory reagents for use as adjuvant therapy in the treatment of gram-negative bacterial sepsis.

=> d his

(FILE 'HOME' ENTERED AT 07:13:29 ON 05 JUN 2001)

FILE 'MEDLINE', CAPLUS, BIOSIS, EMBASE, ENTERED AT 07:13:54 ON 05 JUN 2001

L1	3340 S LBP OR (LIPOSACCHARIDE BINDING PROTEIN)
L2	153 S L1 (P) (VARIANT OR MUTANT OR HYBRID)
L3	46210 S SEPTICEMIA
L4	9 S (L1 OR L2) (P) L3
L5	6 DUPLICATE REMOVE L4 (3 DUPLICATES REMOVED)
L6	2522 S (L1 OR L2) (A) (HUMAN OR MURINE OR RABBIT OR RAT)
L7	729 S (L1 OR L2 OR L6) (P) TREAT?
L8	402 DUPLICATE REMOVE L7 (327 DUPLICATES REMOVED)
L9	65 S L8 AND (COMPOSITION OR AGENT)
L10	2229 S (BACTERICIDAL PERMEABILITY INCREASING PROTEIN) OR BPI
L11	64 S (LIMULUS ANTI-LPS FACTOR) OR LALF
L12	15 S (L1 OR L2 OR L6) (P) L11
L13	9 DUPLICATE REMOVE L12 (6 DUPLICATES REMOVED)

=> log Y

COST IN U.S. DOLLARS	SINCE FILE	ENTRY	TOTAL
FULL ESTIMATED COST	171.41	SESSION	171.56
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	ENTRY	TOTAL
CA SUBSCRIBER PRICE	-24.70	SESSION	-24.70

STN INTERNATIONAL LOGOFF AT 07:33:36 ON 05 JUN 2001